

Unravelling Treatment Response in Multiple Sclerosis

WEDNESDAY, 5 JUNE 2024

- 09.00** **Welcome**
M. Tintoré (Barcelona, SP), T. Chitnis (Boston, US)
- 09.05** **Historical view and aim of Workshop**
X. Montalban (Barcelona, SP)
- 09.10** **Challenges in Treatment Response**
A. Pappolla (Barcelona, SP)
- 09.20** **Methodological aspects of consensus Workshop**
S. Otero – Romero (Barcelona, SP)
- 09.30 - 10.10** **Session 1: Methodological aspects of Heterogeneity of
treatment effect (HTE) analysis**
Chairs: M.P. Sormani (Genoa, IT), G. Cutter (Birmingham, US)
- 09.30** Heterogeneous treatment effect models in MS
M.P. Sormani (Genoa, IT)
- 09.50** A two-stage prediction model for heterogeneous effects of
treatments
K. Chalkou (Bern, CH)
- 10.10** Discussion / Q&A
F. Bovis (Genoa, IT)
Chairs / All Speakers
- 10.30 - 11.00** **Coffee Break**

11.00 - 12.00 **Session 2: Tools for treatment response assessment in Relapsing MS**

Chairs: M. Inglese (Genoa, IT), D. Reich (Bethesda, US)

11.00 **Clinical Tools**

- Relapses and RAW
- Progression: EDSS, MSFC, PIRA, CDW
- Cognitive impairment assessment

M.P. Amato (Florence, IT)

11.15 **Radiological Tools 1**

- T2 lesional assessment
- Gadolinium assessment
- Spinal cord assessment
- Brain and spinal cord volume loss

D. Ontaneda (Cleveland, US)

11.30 **Radiological Tools 2**

- Slowly expanding lesions (SELs)
- Paramagnetic Rim lesions (PRLs)

A. Rovira (Barcelona, SP)

11.45 **Radiological Tools 3**

- Positron emission tomography (PET)

L. Airas (Turku, FI)

12.00 **Discussion / Q&A**

J. Sastre - Garriga (Barcelona, SP)

C. Tur (Barcelona, SP)

Chairs / All Speakers

12.30 - 14.00 **Lunch Break**

- 14.00 - 14.45** **Session 3: Tools for treatment response assessment in Relapsing MS**
Chairs: J. Lycke (Gothenburg, SE), M. Mycko (Olsztyn, PO)
- 14.00 Pharmacogenomics
S. Baranzini (San Francisco, US)
- 14.15 Patient reported outcomes (PROMS)
G. Brichetto (Genoa, IT)
- 14.30 Digitally reported outcomes
T. Ziemssen (Dresden, GER)
- 14.45 Discussion / Q&A
A. Green (San Francisco, US)
Chairs / All Speakers
- 15.15 - 15.45** **Coffee Break**
- 15.45 - 16.30** **Session 4: Tools for treatment response assessment in Relapsing MS**
Chairs: F. Di Pauli (Innsbruck, AT), J. Kuhle (Basel, CH)
- 15.45 sNFL
- In PRMS monitoring
 - sNFL future directions
- J. Kuhle (Basel, CH)*
- 16.00 sGFAP and other biomarkers
- sGFAP in PRMS monitoring
 - sGFAP future directions
 - promising biomarkers
- T. Chitnis (Boston, US)*
- 16.15 Optic coherence tomography
Á. Vidal (Barcelona, SP)
- 16.30 Discussion / Q&A
Chairs / All Speakers
- 17.00** **End of Day 1**
- 19.30** **Dinner at hotel**

THURSDAY, 6 JUNE 2024

09.00 - 10.00 **Session 5: Treatment response assessment across therapies in Relapsing MS**

Chairs: C. Lebrun-Frenay (Nice, FR), C. Gasperini (Rome, IT)

09.00

Platform therapies

- Evidence review
- Current treatment response assessment
- Rebaseline concept and DMT action onset
- Added role of fluid biomarkers
- Role of neutralising antibodies

C. Gasperini (Rome, IT)

9.20

Daily oral therapies

- Evidence review
- Current treatment response assessment
- Rebaseline concept and DMT action onset
- Added role of fluid biomarkers

N. De Stefano (Siena, IT)

09.40

Monoclonal antibodies: Natalizumab and anti-CD20 therapies

- Evidence review
- Current treatment response assessment
- Rebaseline concept and DMT action onset
- Added role of fluid biomarkers
- Role of neutralising antibodies

R. Gold (Bochum, GER)

10.00

Discussion / Q&A

S. Chahin (St. Louis, US)

Chairs / All Speakers

10.30 - 11.00

Coffee Break

11.00 - 11.30 **continuing Session 5: Treatment response assessment across therapies in Relapsing MS**

Chairs: C. Lebrun-Frenay (Nice, FR), C. Gasperini (Rome, IT)

11.00 Reconstitution therapies: Cladribine and Alemtuzumab

- Evidence review
- Current treatment response assessment
- Cladribine: 3^o cycle
- Added role of fluid biomarkers
- Rebaseline concept and DMT action onset
- Relapses during incomplete treatment

J. Oh (Toronto, CA)

11.15 Reconstitution therapies: HSCT

- Evidence review
- Current treatment response assessment and first year assessment

P. Muraro (London, UK)

11.30 Discussion / Q&A

Chairs / All Speakers

12.00 - 13.30 **Lunch Break**

13.30 - 14.45 **Session 6: Treatment response assessment in progressive MS**

Chairs: M. Tintoré (Barcelona, SP), M. Dsouza (Basel, CH)

13.30 Clinical assessment

- How to define treatment response

D. Leppert (Basel, CH)

13.45 Radiological assessment 1

- Slowly expanding lesions (SELs)
- Paramagnetic Rim lesions (PRLs)
- Other measurements

C. Granziera (Basel, CH)

14.00 Radiological assessment 2

- PET

B. Stankoff (Paris, FR)

- 14.15 **Biological assessment**
- Fluid biomarkers in treatment response
- A. Abdelhak (San Francisco, US)*
- 14.30 **PROMS**
- PROMS in treatment response
- G. Comi (Milan, IT)*
- 14.45 **Discussion / Q&A**
- E. Hernandez Martinez (Barcelona, SP)*
C. Oreja (Madrid, SP)
Chairs / All Speakers
- 15.15 - 15.45 Coffee Break**
- 15.45 - 16.45 Session 7: Treatment response across populations**
- Chairs: L. Amezcua (Los Angeles, US), C. Hersh (Las Vegas, US)
- 15.45 **Pregnancy**
- How to define treatment response in pregnancy
- R. Bove (San Francisco, US)*
- 16.00 **Pediatric MS**
- Specific considerations of treatment response in children
- Y. Hachon (London, UK)*
- 16.15 **Low- and middle-income countries: LATAM**
- Rituximab
 - Cyclophosphamide
 - Others
 - Absence of biomarker availability: rebaseline concept
- J. Correale (Buenos Aires, AR)*
- 16.30 **Low- and middle-income countries: Africa**
- Rituximab
 - Cyclophosphamide
 - Others
 - Absence of biomarker availability: rebaseline concept
- D. Saylor (Baltimore, US)*

16.45 Discussion / Q&A
J. Fiol (Denver, US)
L. Freeman (Austin, US)
A. Helme (London, UK)
Chairs / All Speakers

17.15 End of Day 2

19.30 Workshop Dinner

FRIDAY, 7 JUNE 2024

09.00 - 10.30 Discussion of Statements – Part 1
(M. Tintoré, M.P. Sormani, A. Pappolla, X. Montalban)

10.30 - 11.00 Coffee Break

11.00 - 12.00 Discussion of Statements – Part 2
(M. Tintoré, M.P. Sormani, A. Pappolla, X. Montalban)

12.00 - 12.30 Wrap-up and closing remarks

As of 12.30 Lunch and individual departure